U.S. Dupuytren’s Disease Market Size & Outlook, 2022-2030
Related Markets
U.S. dupuytren’s disease market highlights
- The U.S. dupuytren’s disease market generated a revenue of USD 552.2 million in 2022 and is expected to reach USD 834.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.3% from 2023 to 2030.
- In terms of segment, type ii was the largest revenue generating disease type in 2022.
- Type II is the most lucrative disease type segment registering the fastest growth during the forecast period.
Dupuytren’s disease market data book summary
| Market revenue in 2022 | USD 552.2 million |
| Market revenue in 2030 | USD 834.7 million |
| Growth rate | 5.3% (CAGR from 2022 to 2030) |
| Largest segment | Type ii |
| Fastest growing segment | Type II |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Type I, Type II, Type III |
| Key market players worldwide | Bayer AG, Novartis AG ADR, Pfizer Inc, Bristol-Myers Squibb Co, GSK PLC, AstraZeneca PLC, Hikma Pharmaceuticals PLC, LEO Pharma, Fresenius SE & Co KGaA, Nantong Jinghua Pharmaceutical, Actiza Pharmaceutical Pvt. Ltd, Eppendorf, Endo Pharmaceuticals, Spear Pharmaceuticals |
Other key industry trends
- In terms of revenue, U.S. accounted for 13.4% of the global dupuytren’s disease market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. dupuytren’s disease market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 95.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dupuytren’s Disease Market Scope
Dupuytren’s Disease Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Spear Pharmaceuticals | View profile | - | Randolph, New Jersey, United States, North America | http://www.spearpharma.com/ |
| Actiza Pharmaceutical Pvt. Ltd | View profile | 11-50 | https://www.actizapharma.com/ | |
| Nantong Jinghua Pharmaceutical | View profile | 1001-5000 | Nantong, Jiangsu, China, Asia | http://www.jinghuapharm.com/ |
| Hikma Pharmaceuticals PLC | View profile | 2150 | 1 New Burlington Place, London, United Kingdom, W1S 2HR | https://www.hikma.com |
| Endo Pharmaceuticals | View profile | 1001-5000 | Ballsbridge, Dublin, Ireland, Europe | http://www.endo.com |
| Eppendorf | View profile | 1001-5000 | Hamburg, Hamburg, Germany, Europe | https://dasgip.de |
| LEO Pharma | View profile | 1001-5000 | Parsippany, New Jersey, United States, North America | http://www.leo-pharma.us/ |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Fresenius SE & Co KGaA | View profile | 193865 | Else-Kroener-Strasse 1, Bad Homburg, HE, Germany, 61352 | https://www.fresenius.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
U.S. dupuytren’s disease market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dupuytren’s disease market will help companies and investors design strategic landscapes.
Type ii was the largest segment with a revenue share of 62.5% in 2022. Horizon Databook has segmented the U.S. dupuytren’s disease market based on type i, type ii, type iii covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. dupuytren’s disease market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. dupuytren’s disease market databook
-
Our clientele includes a mix of dupuytren’s disease market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dupuytren’s disease market, including forecasts for subscribers. This country databook contains high-level insights into U.S. dupuytren’s disease market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. dupuytrens disease market report size, by disease type, 2018-2030 (US$M)
U.S. Dupuytren’s Disease Market Share, 2022 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
